目的 系统评价T-型CCB治疗高血压合并慢性肾病患者的疗效是否等同或优于ACEI/ARB对这部分患者的疗效。方法 计算机检索Cochrane Library,Pubmed,EMbase,CNKI等数据库,检索时间截止至2012年5月。收集符合纳入标准的临床随机对照试验,采用Revman 5.1对纳入的研究进行meta分析。结果 最终纳入5个临床随机对照研究,563名高血压合并慢性肾病的受试者。Meta分析结果表明,T-型CCB在提高受试者肌酐清除率和肾小球滤过率方面与ACEI/ARB效果相当,但降低蛋白尿的效果不如ACEI/ARB(3个RCTs,389 名受试者,WMD 0.26 g·d-1,95% CI 0.10 to 0.43)。血压的分析结果显示,无论T-型CCB还是ACEI/ARB都具有较强的降压效果。结论 T-型CCB能有效地控制血压和改善肾脏指标,对高血压合并慢性肾病患者有一定疗效。但其降低蛋白尿的效果不如ACEI/ARB,不建议用于蛋白尿是主要症状的高血压合并慢性肾病患者。
Abstract
To evaluate whether T-type CCBs are equivalent with or superior to ACEIs/ARBs on renal outcomes in hupertensive patients with chronic kidney disease. METHODS Cochrane Library, Pubmed, EMbase and CNKI were searched for relevant randomized controlled trials (RCTs) from inception to May 2012. The meta-analysis was performed by Revman 5.1 software. RESULTS Five RCTs (563 subjects) were included in the present study. T-type CCBs performed a pooled improvement in creatinine clearance and glomerular filtration rate similar to ACEIs/ARBs but were inferior to ACEIs/ARBs on reducing proteinuria excretion (three RCTs, 389 subjects, WMD 0.26 g穌-1, 95% CI 0.10 to 0.43), although T-type CCBs and ACEIs/ARBs showed stable anti-hypertensive effect.CONCLUSION Our findings suggest that despite T-type CCBs do offer salutary effects on kidney outcomes and hypertension can be applied to treat hypertensive patients with chronic kidney disease, ACEIs/ARBs might be better choice for pressure control in this target population especially when proteinuria is the main issue of renal dysfunction.
关键词
T-型CCB /
ACEI /
ARB /
高血压 /
慢性肾病
{{custom_keyword}} /
Key words
T-type calcium channel blocker /
angiotensin converting enzyme inhibitor /
angiotensin receptor blockers /
hypertension /
chronic kidney disease
{{custom_keyword}} /
中图分类号：
R459.7
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] LOCATELLI F, DEL VECCHIO L, D′AMICO M, et al. Is it the agent or the blood pressure level that matters for renal protection in chronic nephropathies . J Am Soc Nephrol, 2002, 13(suppl 3): 196-201.[2] KUNDHAL K, LOK C E. Clinical epidemiology of cardiovascular disease in chronic kidney disease .Nephron Clin Pract, 2005, 101(2): 47-52.[3] CASAS J P, CHUA W, LOUKOGEORGAKIS S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes:systematic review and meta-analysis . Lancet, 2005, 366(9502):2026-2033.[4] PETERSON J C, ADLER S, BURKART J M, et al. Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study .Ann Intern Med, 1995, 123(10): 754-762.[5] HAYASHI K, WAKINO S, SUGANO N, et al. Ca2+ channel subtypes and pharmacology in the kidney . Circ Res, 2007, 100(3): 342-353.[6] HAYASHI K, NAGAHAMA T, OKA K, et al. Disparate effects renal of calcium antagonists microcirculation. Hypertens Res, 1996, 19(1): 31-36.[7] DU J S, GAO Z Y. The adverse reactions of the calcium channel blockers . Chin Pharm J(中国药学杂志),1999, 34(9):625-626.[8] XIE S, ZHANG P, JIA Y H, et al.The treatment effects of benidipine in stable angina:Multicenter clinical study .Chin Pharm J(中国药学杂志),2010, 45(9):682-685.[9] FOGARI R, MUGELLINI A, ZOPPI A, et al. Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria .Eur J Clin Pharmacol, 2005, 61(7): 483-490. HAYASHI K, KUMAGAI H, SARUTA T. Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment . Am J Hypertens, 2003, 16(2): 116-122. PENG T, HU Z, XIA Q, et al.A comparative study of the renoprotective effects of benidipine and valsartan in primary hypertensive patients with proteinuria .Arzneimittelforschung, 2009, 59(12): 647-650. SHIBA T, INOUE M, TADA H, et al. Delapril versus manidipine in hypertensive therapy to halt the type-2-diabetes-mellitus-associated nephropathy . Diabetes Res Clin Pract, 2000, 47(2): 97-104. VECCHIO L, POZZI M, SALVETTI A, et al. Efficacy and tolerability of manidipine in the treatment of hypertension in patients with non-diabetic chronic kidney disease without glomerular disease.Prospective, randomized, double-blind study of parallel groups in comparison with enalapril .J Nephrol, 2004, 17(2): 261-269. ISEKI K, IKEMIYA Y, ISEKI C, et al. Proteinuria and the risk of developing end-stage renal disease .Kidney Int, 2003, 63(4): 1468-1474. ZEEUW D D. Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment . Kidney Int, 2004, 66(92): 2-6. SAITO F, FUJITA H, TAKAHASHI A, et al. Renoprotective effect and cost-effectiveness of using benidipine, a calcium channel blocker, to lower the dose of angiotensin receptor blocker in hypertensive patients with albuminuria . Hypertens Res, 2007, 30(1): 39-47. FARAH R, KHAMISY-FARAHR, SHURTI-SWIRSKIR. Calcium channel blocker effect on insulin resistance and inflammatory markers in essential hypertension patients .Int Angiol, 2013, 32(1):85-93.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(1322 KB)
